YPrime Declared Leader in Everest Group’s 2025 eCOA Assessment

BREAKING: YPrime has been officially recognized as a Leader in the Everest Group’s 2025 Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment. This announcement, made earlier today on September 2, 2025, highlights YPrime’s innovative technology and its critical role in streamlining complex clinical trials worldwide.

YPrime’s eCOA platform is distinguished for its ability to deliver high-quality data rapidly and flexibly, catering to the urgent needs of global clinical trials. The recognition signifies YPrime’s commitment to enhancing trial efficiency and patient experience, making it a trusted partner for top pharmaceutical companies and emerging biotechs alike.

Mike Hughes, Chief Product Officer at YPrime, stated, “We’re proud to be named a Leader by Everest Group. Our eCOA platform is built to meet the complexity and speed that today’s clinical trials demand—while simplifying processes and improving the experience for patients, sites, and sponsors alike.” This designation reflects the company’s exceptional capability to execute trials at scale, even under tight deadlines.

The Everest Group PEAK Matrix® evaluates companies based on their vision, capability, and market impact. YPrime’s position in the Leader quadrant underscores its significant contributions, helping sponsors launch studies faster and more efficiently with advanced eCOA solutions.

Mark Maietta, President of YPrime, emphasized the importance of this recognition, stating, “Being named a Leader highlights the strength of our platform and the quality of service we deliver to clinical trial sponsors and CROs every day.” This acknowledgment reinforces YPrime’s ongoing commitment to innovation and operational excellence, essential for conducting successful clinical trials.

YPrime’s eCOA platform is engineered for scalability, designed to meet the intricate demands of today’s global trials. Notably, the introduction of AI-powered localization tools has revolutionized how sponsors approach global study startups. This innovation automates the translation migration process, reducing delays and ensuring linguistic precision, thereby supporting deployments in over 250 languages across more than 100 countries.

In addition to localization tools, YPrime has launched an Automated Data Change Form (DCF) that empowers site staff to execute protocol-compliant data edits in mere minutes, dramatically improving both speed and data integrity. This addresses a significant pain point in traditional eCOA systems, enhancing workflow efficiency.

YPrime is also advancing connected device integration with its glucometer eCOA feature, developed with input from diabetes patients. This capability supports real-time glucose monitoring, crucial for metabolic studies, and improves patient adherence by reducing their burden during trials.

Previously, YPrime was recognized as a Trailblazer in Patient Engagement by Everest Group in 2024, further validating its leadership in creating user-friendly digital tools that enhance patient participation in clinical trials.

YPrime, based in Malvern, Pennsylvania, simplifies clinical trials through a range of solutions including eCOA, IRT, and eConsent. The company’s commitment to speed, flexibility, and quality has made it a preferred partner for leading pharmaceutical companies and emerging biotechs worldwide.

With nearly two decades of proven success, YPrime continues to address the evolving challenges in clinical research, delivering reliable solutions and supporting sponsors in achieving their trial objectives efficiently.

For further information, visit www.yprime.com or contact [email protected].

Stay tuned for more updates as YPrime continues to lead the way in transforming clinical trial methodologies and enhancing patient experiences.